Emerging Markets Ex-China Equities Show Strong Performance and Promising Outlook
Finance

Emerging Markets Ex-China Equities Show Strong Performance and Promising Outlook

authorBy Michele Ferrero
DateAug 08, 2026
Read time2 min

Emerging markets excluding China delivered impressive returns during a dynamic second quarter. This strong performance was primarily fueled by robust commodity prices and appealing valuation metrics within these markets. These factors collectively contributed to one of the most successful quarters on record for this asset class.

The MSCI Emerging Markets ex-China Index Net Total Return, which serves as the benchmark for this segment, saw an outstanding gain of 34.53%. In comparison, the EMM (Emerging Market Momentum) fund, reflecting these market trends, achieved a 29.83% return based on its Net Asset Value and a 28.09% return based on its market price during the same period. This indicates a significant upswing across these markets, despite EMM's slight underperformance relative to its benchmark.

Looking ahead, the prospects for emerging market equities outside of China remain optimistic. The strategic positioning in regions like Korea and Taiwan, focusing on attractively priced technology firms, alongside the structural growth opportunities in India and the benefits of supportive policies and strong commodity demand in Latin America, provide a solid foundation for continued positive performance. This diversified approach, even with targeted off-benchmark investments in countries such as Kazakhstan and Argentina, underscores a confident and forward-thinking investment strategy.

The resilience and growth demonstrated by emerging markets outside of China highlight their potential for investors seeking diversification and higher returns. By strategically investing in regions with strong economic fundamentals and favorable market conditions, these markets can offer significant opportunities. Embracing a global perspective and focusing on intrinsic value are key to navigating and capitalizing on the evolving landscape of international finance.

More Articles
Finance
Farmer Mac's Stellar Performance and Future Outlook
Farmer Mac reported impressive Q1 results with record business volume, increased revenue, and robust core earnings. The company's strong capital position and consistent shareholder returns underpin a positive outlook. This article examines Farmer Mac's recent financial achievements and strategic initiatives, including a planned credit risk transfer program, and evaluates its investment potential.
By Lisa JingAug 08, 2026
Finance
Equity Bancshares: A Strong Buy for Value and Growth
Equity Bancshares (EQBK) presents a compelling investment opportunity, trading at a significant discount to its historical valuation and industry peers. The company's strategic growth through mergers and acquisitions, coupled with a focus on optimizing its asset portfolio, drives robust earnings. Furthermore, consistent capital returns via dividends and share buybacks underscore its commitment to shareholder value. While potential risks like interest margin compression and minor asset quality fluctuations exist, EQBK's overall financial health remains strong, positioning it as an attractive 'BUY' for investors seeking a blend of value and growth.
By David RubensteinAug 08, 2026
Finance
SpaceX's Overvalued Ambitions: A Critical Investment Analysis
This analysis delves into SpaceX's valuation, concluding it's currently a 'sell.' The company's $1.43 trillion equity value heavily relies on overly optimistic projections across its Connectivity, Space, and AI divisions. While Starlink drives profitability, its declining average revenue per user (ARPU) and limited scalability alone can't justify the valuation without extraordinary success in AI or space ventures. Both AI and Space segments are unprofitable and capital-intensive, with AI contracts presenting short-term gains against long-term infrastructure costs, heightening risk. Even with generous valuations, SpaceX's intrinsic value is estimated to be approximately 33% below its market price, suggesting that only significant free cash flow improvements or a substantial stock price reduction would warrant holding the shares.
By Strive MasiyiwaAug 08, 2026
Finance
Pacira BioSciences: Advancing in Musculoskeletal Pain Management and Valuation Growth
Pacira BioSciences is transforming from a single-product pharmaceutical company into a diversified musculoskeletal pain platform. Key developments include EXPAREL's expanded reimbursement, the strategic divestiture of iovera°, and a pipeline of high-value pharmaceutical programs. Despite strong financial performance and promising late-stage catalysts, the company's valuation remains significantly undervalued, indicating strong potential for future growth and investor returns.
By Robert KiyosakiAug 08, 2026
Finance
Keyera's Strategic Transformation in the Canadian NGL Market
Keyera has cemented its position as a central hub for Canadian natural gas liquids (NGLs) through strategic acquisitions, significantly boosting its fee-based revenue and reducing reliance on volatile marketing profits. The company is poised for substantial growth in adjusted EBITDA, driven by expanded infrastructure and robust contract backing, despite facing elevated leverage and integration challenges. This transformation positions Keyera for a potential premium valuation.
By Lisa JingAug 08, 2026